Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
Lucid Diagnostics announces proposed public stock offering
-
Lucid Diagnostics announces proposed public stock offering
-
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
-
Canaccord Genuity on Lucid Diagnostics Inc (LUCD): 'we believe the stock does not reflect the company's long-term growth potential'
-
Lucid Diagnostics to Participate in Upcoming Investor Conferences
-
Lucid Diagnostics (LUCD) Announces Closing of Public Offering of Common Stock
-
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
-
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
-
Lucid Diagnostics (LUCD) Announces Proposed Public Offering of Common Stock
-
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
-
Canaccord Genuity Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
-
Lucid Diagnostics Inc (LUCD) Closes $15.3M Direct Offering
-
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
-
Lucid Diagnostics Inc (LUCD) Prices 13.94M Share Offering at $1.10/sh
-
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
-
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
-
Lucid Diagnostics to Participate in Upcoming Investor Conferences
-
Canaccord Genuity Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
-
Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
-
Lucid Diagnostics to Present at the Canaccord Genuity 43rd Annual Growth Conference
-
Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
-
Lucid Diagnostics Inc (LUCD) PT Lowered to $12 at Canaccord Genuity
-
Lucid Diagnostics to Present at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
-
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
-
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
-
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
-
Lucid Diagnostics (LUCD) IPO Opens, Trades Lower
-
Lucid Diagnostics Inc (LUCD) Prices 5M Share IPO at $14/sh
-
Lucid Diagnostics Announces Pricing of Initial Public Offering
-
Lucid Diagnostics Announces Pricing of Initial Public Offering
-
Lucid Diagnostics Announces Pricing of Initial Public Offering
-
Lucid Diagnostics (LUCD) IPO: 7 Things to Know
-
Lucid Diagnostics Inc (LUCD) Files For up to $57.5M IPO

